A novel lipid-based nanomicelle of docetaxel: Evaluation of antitumor activity and biodistribution

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 3389-3398

  Ma, Mingshu ^a   Hao, Yanli ^a   Liu, Nan ^a   Yin, Zhe ^a   Wang, Lan ^a   Liang, Xingjie ^b   Zhang, Xiaoning ^a  

^a Tsinghua University   (China)

^b NATIONAL CENTER FOR NANOSCIENCE AND TECHNOLOGY   (China)

Author keywords

Antitumor activity; Docetaxel; In vivo optical imaging; Lipid based micelles

Indexed keywords

DOCETAXEL; LIPID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BIOLUMINESCENCE; BREAST CANCER; CANCER INHIBITION; CONTROLLED STUDY; CRITICAL MICELLE CONCENTRATION; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG MECHANISM; DRUG STABILITY; DRUG STRUCTURE; DRUG TISSUE LEVEL; FLUORESCENCE IMAGING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LIGHT SCATTERING; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MELANOMA B16; MICELLE; MOLECULAR IMAGING; MOUSE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PHARMACODYNAMICS; SURVIVAL TIME; TRANSMISSION ELECTRON MICROSCOPY; TUMOR XENOGRAFT;

ANALYSIS OF VARIANCE; ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG STABILITY; HUMANS; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, NUDE; MICELLES; MOLECULAR IMAGING; NANOPARTICLES; SPECTROMETRY, FLUORESCENCE; TAXOIDS; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANIMALIA; MUS MUSCULUS;

EID: 84870354768     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S29827     Document Type: Article

References (32)

1. Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov. 2010;9(8):615-627.
2. Savic R, Luo L, Eisenberg A, Maysinger D. Micellar nanocontainers distribute to defined cytoplasmic organelles. Science. 2003;300(5619): 615-618.
3. Kedar U, Phutane P, Shidhaye S, Kadam V. Advances in polymeric micelles for drug delivery and tumor targeting. Nanomedicine. 2010;6(6):714-729.
4. Valle JW, Armstrong A, Newman C, etal. A phase 2study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction. Invest New Drugs. 2011;29(5):1029-1037.
5. Lee KS, Chung HC, Im SA, etal. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res Treat. 2008;108(2):241-250.
6. Clinicaltrials. gov [homepage on the Internet]. Bethesda, MD: U.S. National Library of Medicine; c1993-2001 [updated January 5, 2012; cited January 7, 2012]. Available from: http://clinicaltrials.gov/. Accessed January 9, 2012.
7. Engels FK, Mathot RA, Verweij J. Alternative drug formulations of docetaxel: a review. Anticancer Drugs. 2007;18(2):95-103.
8. Pharma-ingredients. basf. com [website on the Internet]. Germany: BSF; c2011 [updated December 10, 2011; cited January 7, 2012]. Available from: http://worldaccount.basf.com/wa/NAFTA/Catalog/Pharma/info/BASF/exact/solutol_hs_15. Accessed January 9, 2012.
9. Coon JS, Knudson W, Clodfelter K, Lu B, Weinstein RS. Solutol HS 15, nontoxic polyoxyethylene esters of 12-hydroxystearic acid, reverses multidrug resistance. Cancer Res. 1991;51(3):897-902.
10. Howard MD, Jay M, Dziubla TD, Lu X. PEGylation of nanocarrier drug delivery systems: state of the art. J Biomed Nanotechnol. 2008;4(2): 133-148. doi:10.1166/jbn.2008.021.
11. Musacchio T, Torchilin VP. Recent developments in lipid-based pharmaceutical nanocarriers. Front Biosci. 2011;16:1388-1412.
12. Baker J, Ajani J, Scotté F, etal. Docetaxel-related side effects and their management. Eur J Oncol Nurs. 2009;13(1):49-59.
13. Baker M. Whole-animal imaging: the whole picture. Nature. 2010; 463(7283):977-980.
14. Mora-Huertas CE, Fessi H, Elaissari A. Polymer-based nanocapsules for drug delivery. Int J Pharm. 2010;385(1-2):113-142.
15. Wu C, Hou Y, Deng M, etal. Molecular conformation-controlled vesicle/micelle transition of cationic trimeric surfactants in aqueous solution. Langmuir. 2010;26(11):7922-7927.
16. Wang X, Wang Y, Chen X, Wang J, Zhang X, Zhang Q. NGR-modified micelles enhance their interaction with CD13-overexpressing tumor and endothelial cells. J Control Release. 2009;139(1):56-62.
17. Wang Y, Yang T, Wang X, etal. Materializing sequential killing of tumor vasculature and tumor cells via targeted polymeric micelle system. J Control Release. 2011;149(3):299-306.
18. Baker SD, Zhao M, He P, Carducci MA, Verweij J, Sparreboom A. Simultaneous analysis of docetaxel and the formulation vehicle polysorbate 80in human plasma by liquid chromatography/tandem mass spectrometry. Anal Biochem. 2004;324(2):276-284.
19. Kalchenko V, Shivtiel S, Malina V, etal. Use of lipophilic near-infrared dye in whole-body optical imaging of hematopoietic cell homing. J Biomed Opt. 2006;11(5):050507.
20. Bhaumik S, Gambhir SS. Optical imaging of Renilla luciferase reporter gene expression in living mice. Proc Natl Acad Sci U S A. 2002;99(1): 377-382.
21. Zhan C, Gu B, Xie C, Li J, Liu Y, Lu W. Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect. J Control Release. 2010;143(1):136-142.
22. Dreher MR, Liu W, Michelich CR, Dewhirst MW, Yuan F, Chilkoti A. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J Natl Cancer Inst. 2006;98(5):335-344.
23. Chen J, Zhou B, Li Q, etal. PLLA-PEG-TCH-labeled bioactive molecule nanofibers for tissue engineering. Int J Nanomedicine. 2011;6: 2533-2542.
24. Torchilin VP. Structure and design of polymeric surfactant-based drug delivery systems. J Control Release. 2001;73(2-3):137-172.
25. Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Res. 1987;47(12):3039-3051.
26. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000;65(1-2):271-284.
27. Yoo JW, Chambers E, Mitragotri S. Factors that control the circulation time of nanoparticles in blood: challenges, solutions and future prospects. Curr Pharm Des. 2010;16(21):2298-3307.
28. Caliceti P, Veronese FM. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev. 2003;55(10):1261-1277.
29. Lukyanov AN, Torchilin VP. Micelles from lipid derivatives of water-soluble polymers as delivery systems for poorly soluble drugs. Adv Drug Deliv Rev. 2004;56(9):1273-1289.
30. Bissery MC. Preclinical pharmacology of docetaxel. Eur J Cancer. 1995;31A Suppl 4:S1-S6.
31. Portney NG, Ozkan M. Nano-oncology: drug delivery, imaging, and sensing. Anal Bioanal Chem. 2006;384(3):620-630.
32. Contag CH, Ross BD. It's not just about anatomy: in vivo bioluminescence imaging as an eyepiece into biology. J Magn Reson Imaging. 2002;16(4):378-387.